This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Oncology  • Oncology, Other  • Cardiovascular System  • Statistics and Research Methods  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(8):813-815.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

After a months-long investigation, the US Food and Drug Administration (FDA) reiterated on January 8 that ezetimibe/simvastatin is an acceptable medication for reducing levels of low-density lipoprotein cholesterol (LDL-C).

Blockage in a coronary artery sets the stage for myocardial infarction. A study that is scheduled to be completed in 2012 may reveal whether ezetimibe/simvastatin, which lowers levels of low-density lipoprotein cholesterol, reduces cardiovascular death and major cardiovascular events. (Photo credit: GJLP/www.sciencesource.com)

The agency's review of ezetimibe/simvastatin was prompted when the drug combination's efficacy was questioned based on data released in March 2008 from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. The study's investigators concluded that the relatively expensive proprietary drug produced greater reductions in levels of LDL-C than did simvastatin alone but resulted in similar changes in arterial intima-media thickness, a surrogate measurement for atherosclerosis progression, a risk factor for cardiovascular disease . . . [Full Text of this Article]

CONTROVERSY



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?